| 3.43 0.02 (0.59%) | 01-08 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.63 | 1-year : | 6.86 |
| Resists | First : | 4.82 | Second : | 5.88 |
| Pivot price | 3.58  |
|||
| Supports | First : | 3.11 | Second : | 2.59 |
| MAs | MA(5) : | 3.35 |
MA(20) : | 3.8 |
| MA(100) : | 5.8 |
MA(250) : | 58.79 |
|
| MACD | MACD : | -0.5  |
Signal : | -0.5 |
| %K %D | K(14,3) : | 18.9 |
D(3) : | 11.3 |
| RSI | RSI(14): 36.1 |
|||
| 52-week | High : | 519 | Low : | 3.11 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ HIND ] has closed above bottom band by 33.4%. Bollinger Bands are 68.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.66 - 3.68 | 3.68 - 3.69 |
| Low: | 3.31 - 3.33 | 3.33 - 3.34 |
| Close: | 3.4 - 3.43 | 3.43 - 3.45 |
Vyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States and global markets. The company was founded in 2017 and is based in Princeton, New Jersey.
Mon, 29 Dec 2025
We're Not Very Worried About Vyome Holdings' (NASDAQ:HIND) Cash Burn Rate - Yahoo Finance
Tue, 23 Dec 2025
Vyome Holdings Signs Letter of Intent With Remus Capital Series B II - TradingView — Track All Markets
Fri, 05 Dec 2025
HIND Stock Price and Chart — NASDAQ:HIND - TradingView — Track All Markets
Tue, 18 Nov 2025
Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing - Business Wire
Tue, 04 Nov 2025
Vyome Holdings Announces Results of Annual Shareholder Meeting - Business Wire
Wed, 17 Sep 2025
HIND Stock Rallies 70% Pre-Market Today – Find Out Why - Stocktwits
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 1.54e+006 (%) |
| Held by Institutions | 42.1 (%) |
| Shares Short | 35 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.63e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 508.9 % |
| Return on Equity (ttm) | -24.6 % |
| Qtrly Rev. Growth | 344590 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 76870 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|